Invitae Corporation (NVTA): Price and Financial Metrics


Invitae Corporation (NVTA): $31.65

-0.14 (-0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVTA POWR Grades


  • Growth is the dimension where NVTA ranks best; there it ranks ahead of 63.48% of US stocks.
  • The strongest trend for NVTA is in Value, which has been heading up over the past 48 weeks.
  • NVTA's current lowest rank is in the Sentiment metric (where it is better than 3.35% of US stocks).

NVTA Stock Summary

  • NVTA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 692.3 -- higher than 95.6% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 424.02%, Invitae Corp's debt growth rate surpasses 97.38% of about US stocks.
  • As for revenue growth, note that NVTA's revenue has grown 66.82% over the past 12 months; that beats the revenue growth of 90.36% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Invitae Corp are CHGG, QLYS, GH, MPWR, and MCFE.
  • NVTA's SEC filings can be seen here. And to visit Invitae Corp's official web site, go to www.invitae.com.

NVTA Valuation Summary

  • In comparison to the median Healthcare stock, NVTA's EV/EBIT ratio is 159.39% lower, now standing at -17.4.
  • NVTA's price/sales ratio has moved down 3416.5 over the prior 80 months.
  • Over the past 80 months, NVTA's price/earnings ratio has gone down 0.3.

Below are key valuation metrics over time for NVTA.

Stock Date P/S P/B P/E EV/EBIT
NVTA 2021-08-31 16.6 2.4 -20.6 -17.4
NVTA 2021-08-30 16.3 2.4 -20.2 -17.1
NVTA 2021-08-27 16.1 2.4 -20.1 -17.0
NVTA 2021-08-26 15.5 2.3 -19.3 -16.3
NVTA 2021-08-25 15.6 2.3 -19.3 -16.4
NVTA 2021-08-24 15.4 2.3 -19.2 -16.3

NVTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVTA has a Quality Grade of D, ranking ahead of 12.95% of graded US stocks.
  • NVTA's asset turnover comes in at 0.118 -- ranking 72nd of 80 Healthcare stocks.
  • BKD, CHE, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.

The table below shows NVTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.118 0.281 -0.331
2021-03-31 0.139 0.268 -0.887
2020-12-31 0.183 0.291 -1.070
2020-09-30 0.284 0.321 -0.721
2020-06-30 0.280 0.347 -0.790
2020-03-31 0.336 0.429 -0.705

NVTA Stock Price Chart Interactive Chart >

Price chart for NVTA

NVTA Price/Volume Stats

Current price $31.65 52-week high $61.59
Prev. close $31.79 52-week low $24.16
Day low $31.43 Volume 335,882
Day high $32.12 Avg. volume 3,842,112
50-day MA $28.83 Dividend yield N/A
200-day MA $37.11 Market Cap 6.88B

Invitae Corporation (NVTA) Company Bio


Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.


NVTA Latest News Stream


Event/Time News Detail
Loading, please wait...

NVTA Latest Social Stream


Loading social stream, please wait...

View Full NVTA Social Stream

Latest NVTA News From Around the Web

Below are the latest news stories about Invitae Corp that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego

PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.

Yahoo | September 21, 2021

Invitae (NVTA) Presents At Ciitizen Announcement Conference Call Presentation - Slideshow

The following slide deck was published by Invitae Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | September 20, 2021

Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying

If you're Cathie Wood, founder, and CEO of ARK Invest, you keep buying more. Shares of life-science equipment manufacturer Berkeley Lights (NASDAQ: BLI) took a hit last week, and two ARK Invest ETFs quickly bought more. Wood also bought two genomics stocks that have tanked this year, Personalis (NASDAQ: PSNL) and Invitae (NYSE: NVTA).

Yahoo | September 20, 2021

Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business. “We are thrilled to welcome Andre, Dalila, Laura and Omar to the expanding leadership team here at Dante,” said Andrea Riposati, CEO of Dante Labs. “As we work to deliver a m

Yahoo | September 14, 2021

What Can Investors Learn from Invitae’s Newly Added Risk Factors?

Invitae (NVTA) is an American medical genetics testing company. The company is leveraging its acquisitions to enhance its offerings. Let’s take a look at Invitae’s latest financial performance, corporate developments, and risk factors. Invitae’s Q2 Financial Results and 2021 Guidance Revenue increased 152% year-over-year to $116.3 million in the second quarter, exceeding consensus estimates of $108.3 million. Invitae posted an adjusted loss per share of $0.85. That marked an improvement from a loss per share of $0.97 in the same quarter last year but missed consensus estimates of a loss per share of $0.65. Invitae ended Q2 with $1.54 billion in cash. (See Invitae stock charts on TipRanks).

Neha Gupta on TipRanks | September 10, 2021

Read More 'NVTA' Stories Here

NVTA Price Returns

1-mo 15.34%
3-mo -7.59%
6-mo -8.13%
1-year -26.57%
3-year 89.29%
5-year 275.44%
YTD -24.30%
2020 159.21%
2019 45.84%
2018 21.81%
2017 14.36%
2016 -3.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8953 seconds.